Top 50 Health Care Startup Investors in Switzerland in January 2025
A list of 50 angel investors and VC (Venture Capital) funds that invest in Health care startups based in Switzerland. We rank investors based on the number of investments they made in Health care companies from Switzerland. We update this investor list every month.Top 50 Health Care Startup Investors in Switzerland in January 2025
Investor | Health Care Switzerland investments |
---|---|
Zürcher Kantonal Bank | 50 |
Verve Ventures | 39 |
Foundation for Innovation and Technology (FIT) | 32 |
BioMedPartners | 19 |
VI Partners | 16 |
redalpine | 13 |
Eclosion SA | 12 |
Schroder Adveq | 10 |
M Ventures | 9 |
HTGF | High-Tech Gruenderfonds | 9 |
SICTIC | 9 |
Founderful | 8 |
3wVentures | 8 |
Kinled Holding | 8 |
GoBeyond | 8 |
Bernina BioInvest | 8 |
StartAngels Network | 8 |
b2venture | 7 |
Polytech Ventures | 7 |
Fongit Seed Invest | 7 |
4FO Ventures | 7 |
Swisscom Ventures | 7 |
Novartis Venture Fund | 7 |
Sofinnova Partners | 6 |
OCCIDENT | 6 |
Lichtsteiner Foundation | 6 |
Alpana Ventures | 6 |
BlueOcean Ventures | 6 |
Zühlke Ventures AG | 6 |
Joyance Partners | 6 |
Novo Holdings | 6 |
EQT Life Sciences | 6 |
Versant Ventures | 6 |
Ralph Gygax | 5 |
Pureos Bioventures | 5 |
ETH Zurich Foundation | 5 |
Sunstone Life Science Ventures | 5 |
Index Ventures | 4 |
Penny Schiffer | 4 |
Werner Hoffmann | 4 |
Aravis Ventures | 4 |
SOSV | 4 |
Patrick Lütjens | 4 |
Neomed Management | 4 |
New Enterprise Associates | 4 |
Good Seed Ventures | 4 |
Startfeld | 4 |
EIT Health | 4 |
Nina Capital | 4 |
BB Biotech Ventures | 4 |
Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Seed, Series A, Funding Round
- Switzerland, Japan, Spain
Portfolio highlights
- Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
- Retinai — RetinAI optimises and simplifies clinics, research and pharmaceutical workflows to improve healthcare. To achieve this goal, the company builds tools to collect, analyze and organize health data, empowering healthcare professionals and patients with automatic image and data analysis supported by advanced machine learning. RetinAI has proprietarytechnology that provides unforeseen image quality enhancement, as well as automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies and device manufacturers at similar level of performance as a human would produce.
- Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, France, Germany
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
- Orakl Oncology — Cultivated with love by the Orakl team.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Debt Financing, Grant, Seed
- Switzerland, France
Portfolio highlights
- Aspivix — ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps).
- Xemperia — Xemperia provides diagnostic solutions that helps to detect breast cancer and early diagnosis of relapses.
- Ex Nunc Intelligence — Ex Nunc Intelligence provides professionals with thorough summaries of legal information, credible responses to legal issues, and automated legal document preparation features.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Switzerland, Germany, France
Portfolio highlights
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
- TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Series A, Series B, Series C
- Switzerland, Germany, United States
Portfolio highlights
- Oplit — Oplit is a production planning platform that provides software and support to help industrials boost operations profitability.
- XO Life — XO Life is to build the largest real-world evidence platform for patient insights for all medications and therapies. Together with one of Europe's leading research institutes for patient-centered research, the PROMIS Institute Germany of the Charité, and various pharmaceutical manufacturers, patient experiences are to be recorded in astandardized and systematic manner across a wide range of diseases. Patients are to be enabled to record their therapy course and outcome independently as well as scientifically validated so that these patient insights from real treatment practice can be used in the life science industry and by medical professions.
- Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Series A, Seed, Series B
- Germany, Switzerland, United Kingdom
Portfolio highlights
- 9fin — 9fin is a leading provider of debt market intelligence and offers everything you need to analyse a credit, or win a mandate in one AI-powered platform
- Apaleo — Transform your hospitality business with an open platform. Easily connect 3rd party applications to build a best-in-class tech stack for your hotel
- OrthoPulse — OrthoPulse is a medical device manufacturer that produces dental care equipment, treatment control apps, and photo biomodulation solutions.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Seed, Series C, Funding Round
- Switzerland
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- Switzerland, United States, India
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
- IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- Pagent — Pagent develops AI systems.
- Refoxy Pharma — Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity.
- Lindis Blood Care — Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.
Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Pre-Seed, Funding Round
- Switzerland, Germany, United Kingdom
Portfolio highlights
- Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
- Creaitor — Creaitor is the ultimate solution for content producers, offering a comprehensive suite of AI tools and integrated SEO features. Streamline your content creation process and optimize your online presence with our powerful platform.
- Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Pre-Seed, Seed, Series A
- Switzerland, United Kingdom, Canada
Portfolio highlights
- Sallea — Sallea is dedicated to pioneering a sustainable future in meat and fish consumption by developing innovative structures for cellular agriculture. This approach allows cells to grow into textured and flavorful whole cuts, ensuring that the products are not only cruelty-free but also safe for consumers. By focusing on these unique methods, Salleaaims to transform the way we think about protein sources, making them more environmentally friendly and ethically produced.
- Apheros — Apheros is a metal foam cooling solutions company. It offers a patent-pending, easily scalable manufacturing approach for metal foams with unique cooling qualities.
- Kyan Health — Prioritise your employees' mental health and well-being with Kyan Health. Our evidence-based solutions address employees' mental well-being, stress at work & boost your workforce productivity.
3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Angel, Series A
- Switzerland, Spain, Austria
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU — GUURU's Community Solution enables trustworthy and authentic live conversations between shoppers and your customer community.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more
Investment focus
- Biotechnology, Health Care, Financial Services
- Seed, Funding Round, Series A
- United Kingdom, United States, Switzerland
Portfolio highlights
- Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
- OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
- Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more
Investment focus
- Information Technology, Medical, Software
- Funding Round, Seed, Series A
- Switzerland, Germany, United Kingdom
Portfolio highlights
- LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
- AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
- Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
Bernina BioInvest is an investment Firm.
Show more
Investment focus
- Biotechnology, Health Care, Biopharma
- Seed, Series A, Series B
- Switzerland
Portfolio highlights
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more
Investment focus
- Medical Device, Health Care, Medical
- Seed, Series A, Series B
- Switzerland, Brazil
Portfolio highlights
- Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
- Pipra — PIPRA AG (Pre-Interventional Preventive Risk assessment) is developing a cutting-edge AI-based pre-operative test to assess a patient's risk of suffering from cognitive disorders after surgery.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Seed, Series B
- Germany, Switzerland, United Kingdom
Portfolio highlights
- 1Komma5° — KOMMA5 ° offers all owners of electric vehicles free electricity, which we refinance through trading with so-called GHG quotas. 1KOMMA5 ° encourages to lead a self-determined and CO2-neutral life.
- Predium — Predium is the software platform for real estate owners to measure, manage and communicate their ESG performance.
- Quanta — OG Home description
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more
Investment focus
- Financial Services, FinTech, Software
- Seed, Series A, Funding Round
- Switzerland, United States, Spain
Portfolio highlights
- yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
- Relai — Relai is the easiest way to invest in Bitcoin for the long-term investor. A simple and intuitive app that allows users to buy and sell Bitcoin directly from their bank account within 1 minute, without registration, KYC verification or deposits. It was founded in 2019 and is headquartered in Zurich, Switzerland.
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Seed, Series A, Series B
- Switzerland
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
4FO Ventures
Show more
Investment focus
- Artificial Intelligence, Health Care, Medical
- Series A, Seed, Series B
- Switzerland
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more
Investment focus
- Software, SaaS, Information Technology
- Funding Round, Series B, Series A
- Switzerland, United States, United Kingdom
Portfolio highlights
- xFarm Technologies — The agricultural business is becoming more and more complex due to legal requirements and product certification. On the other hand, technologies evolve and create opportunity. xFarm is a startup that aims at the digitization of agriculture, providing innovative tools that can support farmers and food supply chain's stakeholders in themanagement of their companies. Created by farmers and tailored to the agricultural sector, its main focus is on ease of use, intuitiveness and complete adaptability to agricultural realities. The digital ecosystem includes a free agricultural application, available on both mobile and desktop and integrated with advanced premium modules, a dashboard Analytics dedicated to professionals and a line of IoT sensors selected, optimized and connected by xFarm.
- ANYbotics — ANYbotics provides autonomous legged robots for industrial applications to provide high availability and reliability in automated routine inspections.
- Kyan Health — Prioritise your employees' mental health and well-being with Kyan Health. Our evidence-based solutions address employees' mental well-being, stress at work & boost your workforce productivity.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
- Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
- Alesta Therapeutics — Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic approaches to treat cancer
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
- Noema Pharma — BEYOND SYMPTOM CONTROL Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their li ...
- Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments.
Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series B, Series C
- Germany, Switzerland, Slovenia
Portfolio highlights
- ReCatalyst — REvolutionizing the way we make CATALYSTs for hydrogen technologies
- Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Seed, Series A
- Switzerland
Portfolio highlights
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
- Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.
Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more
Investment focus
- Software, FinTech, Information Technology
- Seed, Series A, Funding Round
- United States, Switzerland, Germany
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
- Tinamu — Tinamu Labs has developed a technology that converts commercially available drones into camera equipment reaching professional standards.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland.
BlueOcean Ventures is based in Geneva, Switzerland.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Series A, Seed, Series B
- Switzerland, India, France
Portfolio highlights
- nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
- CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
- 99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors
Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Seed, Series B
- Switzerland, Sweden, United States
Portfolio highlights
- Evismo — Evismo provides diagnostics services in Switzerland
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- Flow Neuroscience — Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry.
Joyance Partners invests in companies that, through science and tech, cultivate joy to improve how we live, focusing on the health and consumer sectors from Pre-Seed to Series A.
Show more
Investment focus
- Health Care, Biotechnology, Wellness
- Seed, Series A, Pre-Seed
- United States, Germany, United Kingdom
Portfolio highlights
- JOYA — JOYA is the first employee skincare and wellness benefit platform. The company's goal is to provide tailored access to services such as skin cancer screenings, skin condition treatment, anti-aging, acne, and hair loss care from reputable physicians at an accessible cost.
- Kyan Health — Prioritise your employees' mental health and well-being with Kyan Health. Our evidence-based solutions address employees' mental well-being, stress at work & boost your workforce productivity.
- World Class Health — Access top 1% global healthcare with World Class Health. Superior patient experience & reduced employer spend. Explore our Global Benefits today.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
- Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
- Numab — Numab Therapeutics AG
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
- Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- 858 Therapeutics — 858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Pep2Tango Therapeutics — Pep2Tango Therapeutics is a biotechnology company that offers superior unimolecular multi-receptor drugs for obesity and related disorders.
Ralph Gygax is a Chief Administrative Officer at SWISS Gate AG. He attended KV, SVIT from 1999 to 2007.
Show more
Investment focus
- Cannabis, Wellness, Cosmetics
- Seed, Pre-Seed, Series A
- Switzerland
Portfolio highlights
- SWISS Gate AG — SWISS Gate AG is a family-run Swiss company founded in November 2019 by brothers Dominic, Marco & Michael Hoffmann with the support of their father Werner Hoffmann and uncle Ralph Gygax.SWISS Gate AG focuses with its positioning on the areas of Lifestyle & Wellbeing. The offered product assortment ranges from CBD Anti-Aging and Day Creamsto Skin Creams as well as Shampoo, Shower Gel or Conditioner to Hemp Foods like Hemp Tea or Hemp Seed Oils to CBD Hemp Flowers to CBD Hemp Oil for humans and animals.SWISS Gate AG exclusively distributes its products of the company-owned brands Herbalea and Old Donald's through selected resellers as well as through the company-owned e-commerce channel cbuy.ch - Alles Gute aus Cannabis.SWISS Gate AG manufactures all products together with exclusive partners from the cosmetics, food & consumer goods industry and has the exclusive production & distribution rights over the products.SWISS Gate AG has launched its Series A financing round in mid-September 2021 with the goal to raise CHF 5'000'000. Currently, CHF 200,000 of this amount has been raised. The financing round is currently open - interested parties can contact CEO Marco Hoffmann directly via the contact details.
Venture capital for companies developing innovative therapeutics.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series C, Seed
- Switzerland, France, The Netherlands
Portfolio highlights
- Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
ETH Zurich Foundation is an independent, non-profit-making foundation under private law for the promotion of education and research at ETH Zurich.
Show more
Investment focus
- Information Technology, Medical Device, Medical
- Seed, Grant, Series A
- Switzerland
Portfolio highlights
- 8links — Advanced Battery Tech at Scale with 8inks: Revolutionize cell design, manufacturing, and chemistry for TWh-level solutions .
- Rrreefs — Rrreefs rebuilds damaged coral reefs using their scientifically developed modular reef system. Using 3D-printing technology, they aim to scale up and bring back abundant marine life, create new underwater attractions for ecotourism and to raise awareness (tourists), and protect coastlines.
- Microcaps — Microcaps provides a novel solution to encapsulate ingredients naturally, protect them an enhance them with high-end appearence
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more
Investment focus
- Software, E-Commerce, Internet
- Series A, Series B, Seed
- United States, United Kingdom, France
Portfolio highlights
- Cartesia — Cartesia provides real-time multimodal intelligence for all devices. Its objective is to develop the next generation of AI: pervasive, interactive intelligence that operates everywhere.
- Albert Invent — 1000’s of scientists, technicians, and engineers across 30+ countries rely on Albert’s end-to-end Cloud Platform to accelerate the innovation of new materials. With Albert, R&D organizations get the data insights and tools needed to increase speed to market, automate regulatory compliance, and heighten the impact of new products.Built fromthe ground up for the chemical and material science industry, the Albert Platform connects R&D processes and creates a single data source of truth across the R&D organization. Augmented with AI, machine learning and a comprehensive materials database, key platform functionality includes inventory, worksheets, workflows, tasks, and more. www.albertinvent.com
- Sublime Security — Sublime lets you write, run, and share rules to block phishing attacks, hunt for threats, and more.
Penny Schiffer - CEO & Co-founder @ Raized.ai
Show more
Investment focus
- Health Care, Medical, Finance
- Funding Round, Seed, Series A
- Switzerland, Germany, United Kingdom
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- Enterprise Bot — Cost-effective Conversational AI solutions transforming customer interaction for global enterprises. Discover cutting-edge chat, email, and voice tech.
- Scientific Visual — Scientific Visual supplies quality control workstations to visualize defects in non-polished sapphire such as watch covers, ingots and wafers.
Professional experience:
Expert for Risk Management and Public Relations
Strategic & operational responsibility Compliance & Safety Management
Decades of leadership experience as colonel & professional military pilot in the Swiss Air Force
Show more
Investment focus
- Cannabis, Wellness, Cosmetics
- Seed, Series A
- Switzerland
Portfolio highlights
- SWISS Gate AG — SWISS Gate AG is a family-run Swiss company founded in November 2019 by brothers Dominic, Marco & Michael Hoffmann with the support of their father Werner Hoffmann and uncle Ralph Gygax.SWISS Gate AG focuses with its positioning on the areas of Lifestyle & Wellbeing. The offered product assortment ranges from CBD Anti-Aging and Day Creamsto Skin Creams as well as Shampoo, Shower Gel or Conditioner to Hemp Foods like Hemp Tea or Hemp Seed Oils to CBD Hemp Flowers to CBD Hemp Oil for humans and animals.SWISS Gate AG exclusively distributes its products of the company-owned brands Herbalea and Old Donald's through selected resellers as well as through the company-owned e-commerce channel cbuy.ch - Alles Gute aus Cannabis.SWISS Gate AG manufactures all products together with exclusive partners from the cosmetics, food & consumer goods industry and has the exclusive production & distribution rights over the products.SWISS Gate AG has launched its Series A financing round in mid-September 2021 with the goal to raise CHF 5'000'000. Currently, CHF 200,000 of this amount has been raised. The financing round is currently open - interested parties can contact CEO Marco Hoffmann directly via the contact details.
Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- Switzerland, United States, Denmark
Portfolio highlights
- Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
- Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
- Hedera-22 — Hedera-22 expanded its scope to include the identification of natural products through the use of in-house bio-informatic prediction technologies.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Patrick Lütjens is an investor, an Experienced Senior Consultant with a demonstrated history of working in the venture capital and private equity industry.
Show more
Investment focus
- iOS, SaaS, Mobile
- Seed, Angel, Series A
- Switzerland
Portfolio highlights
- Uepaa® — Uepaa AG is the Lone Worker Safety and Peer2Peer (P2P) communication pioneer for mobile devices. After 10+ years of research, Uepaa AG has developed a revolutionary wireless P2P communication technology. Its first product - the Uepaa! Safety app - launched in 2013, successfully showcased this technology’s leadership position. This award-winningproduct evolved into today's industry standard for mobile-based lone worker safety protection. The daily companion for thousands of employees and field forces - working at risk or alone. Uepaa AG, founded in January 2012 by Mathias Haussmann and Dr Franck Legendre, is a Swiss ETH spin-off, headquartered in Zürich.
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series C, Funding Round
- Switzerland, United States, Italy
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
- JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series B, Series A, Series C
- United States, India, China
Portfolio highlights
- FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
- Ouro Medicines — Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.
Show more
Investment focus
- Food and Beverage, Food Processing, Biotechnology
- Seed, Series A, Pre-Seed
- Germany, Israel, United States
Portfolio highlights
- Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
- Libre Foods — MEAT, BUT MAKE IT MUSHROOMS. GET READY TO TASTE THE POWER OF FUNGI
- Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.
Startfeld is the innovation and start-up network in the St.GallenBodenseeArea. In every phase of innovation, they support both ambitious entrepreneurs and established SME, who are open to new impulses and development.
Show more
Investment focus
- Health Care, Wellness, Medical
- Seed
- Switzerland
Portfolio highlights
- Nahtlos — Nahtlos is a developer of a textile ECG carrier without glue intended to provide long-term, continuous monitoring of heart activity. In order to create a modular and highly flexible ECG system, the company's device consists of a ribbon carrier with clip-in electrodes that are based on a patented electrode structure that can be easily adjustedto different body shapes. This allows doctors to increase patient comfort by swapping out the conductive gel used in gel electrodes.
- OnlineDoctor — OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly (within 48h), location-independent and cost-effectively by an independent dermatologist. OnlineDoctor is suitable for the evaluation of all kinds of skin problems such as rash, eczema, birthmark and many more. The company'suncomplicated, high-quality platform provides a service that benefits all parties.
- Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more
Investment focus
- Health Care, Medical Device, Medical
- Grant, Pre-Seed, Seed
- United Kingdom, Spain, Ireland
Portfolio highlights
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
- Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more
Investment focus
- Health Care, Artificial Intelligence, Software
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Austria
Portfolio highlights
- Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Lillian Care — Lillian is building a nationwide network of health facilities in Germany.
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series C, Series A, Funding Round
- United States, Switzerland, Italy
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Moderna — Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
- Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.
Investors by industry
Consumer
Hardware
Climate
Proptech
Gaming
Google
Marketplace
Biotech
Impact
Community
Energy
FinTech
Artificial intelligence
Health Care
EdTech
Sustainability
Venture Capital
Real Estate
Retail
Clean Energy
Food and Beverage
B2B
Video Games
Web3
Photography
Education
Big Data
Finance
Financial Services
Payments
Beauty
Publishing
Infrastructure
Organic Food
Social Network
Social Media
Digital Media
Art
Medical
Android
Franchise
Mobile
Local
Music
Legal
Enterprise Software
eSports
Construction
Sports
Internet
Wellness
Email
Manufacturing
Recruiting
Mobile Advertising
Travel
Hospitality
Cannabis
Fitness
Biotechnology
Platforms
Wine And Spirits
Automotive
Social
Medical Device
Crowdfunding
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Film
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Germany
United Kingdom
Canada
United States
New Zealand
South Korea
Ireland
India
Australia
Africa
Sri Lanka
Europe
Middle East
China
Qatar
Vietnam
Armenia
Oceania
Brazil
Indonesia
Asia
South Africa
Spain
Saudi Arabia
Japan
Singapore
Estonia
Bermuda
LATAM
Gibraltar
Belarus
Croatia
Ethiopia
Belize
Liechtenstein
Egypt
Georgia
France
Denmark
Costa Rica
Greece
Mauritius
Czech Republic
Hungary
Ecuador
Faroe Islands
Lithuania
Chile
Ghana
Finland
Italy
Bahrain
Philippines
Algeria
Hong Kong
Belgium
Mali
Bulgaria
Liberia
Jersey
Barbados
Malaysia
Senegal
Uruguay
Puerto Rico
Israel
Sweden
Malta
El Salvador
Sierra Leone
Uganda
Lebanon
Slovenia
Norway
Taiwan
Togo
Seychelles
Myanmar
Zambia
Venezuela
Tajikistan
Zimbabwe
Morocco
Russian Federation
Turkey
Tunisia
Uzbekistan
Thailand
Peru
Rwanda
San Marino
Serbia
Tanzania
Ukraine
Nicaragua
Portugal
Poland
Mexico
Dominican Republic
Bahamas
Panama
Iceland
Namibia
Nigeria
Azerbaijan
Iraq
United Arab Emirates
Jamaica
Kuwait
Honduras
Isle of Man
Luxembourg
Bolivia
Jordan
Albania
Pakistan
Bangladesh
Argentina
Romania
Grenada
Kenya
Kazakhstan
Cayman Islands
Cambodia
Cyprus
Latvia
Oman
Cameroon
Austria
Switzerland
Colombia
Guatemala
Marshall Islands
Investors in Switzerland by industry
Crowdfunding
Venture Capital
Film
Transportation
eSports
Cryptocurrency
Finance
Food and Beverage
Medical
Wellness
Fitness
Medical Device
Email
Hardware
Internet
Social Media
Social Network
Digital Media
Manufacturing
Music
Android
Mobile
Blockchain
Construction
Software
Legal
Enterprise Software
Sports
Automotive
Hospitality
Travel
InsurTech
Biotechnology
Recruiting
Mobile Advertising
Platforms
FinTech
Enterprise
Consumer
Health Care
EdTech
Climate
Energy
Sustainability
Proptech
SaaS
Marketplace
Artificial intelligence
Community
Gaming
Mobile Apps
Fashion
Web3
B2B
Life Science
Sporting Goods
Publishing
Education
Clean Energy
Renewable Energy
Financial Services
Real Estate
Beauty
Payments
Oil and Gas
CleanTech
Organic Food
Impact
Social Impact
Social
Restaurants
Infrastructure
Non Profit
Agriculture (agtech)
Media (entertainment)
Biotech
Video Games
Big Data
Retail